BioXcel Therapeutics Stock: Boldly Entering The Danger Zone With IGALMI Launch
peepo/E+ via Getty Images This is my first take on BioXcel (NASDAQ:BTAI). In Q2, 2022, it prepared for the launch of its IGALMI (dexmedetomidine, BXCL501) sublingual film for the acute treatment of agitation associated with […]
